icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
4zYmk3PpUh794kgW
Listen
